Investigational Drug Information for CC-92480
✉ Email this page to a colleague
What is the drug development status for CC-92480?
CC-92480 is an investigational drug.
There have been 11 clinical trials for CC-92480.
The most recent clinical trial was a Phase 1 trial, which was initiated on September 30th 2022.
The most common disease conditions in clinical trials are Neoplasms, Plasma Cell, Multiple Myeloma, and Liver Diseases. The leading clinical trial sponsors are Celgene, Bristol-Myers Squibb, and [disabled in preview].
There are two US patents protecting this investigational drug and eighteen international patents.
Summary for CC-92480
US Patents | 2 |
International Patents | 18 |
US Patent Applications | 19 |
WIPO Patent Applications | 10 |
Japanese Patent Applications | 4 |
Clinical Trial Progress | Phase 1 (2022-09-30) |
Vendors | 26 |
Recent Clinical Trials for CC-92480
Title | Sponsor | Phase |
---|---|---|
A Study of Mezigdomide in Healthy Participants and Participants With Hepatic Impairment | Bristol-Myers Squibb | Phase 1 |
A Study to Evaluate CC-92480 in Combination With Carfilzomib and Dexamethasone (480Kd) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2) | Bristol-Myers Squibb | Phase 3 |
A Study to Evaluate CC-92480, Bortezomib and Dexamethasone (480Vd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | Bristol-Myers Squibb | Phase 3 |
Clinical Trial Summary for CC-92480
Top disease conditions for CC-92480
Top clinical trial sponsors for CC-92480
US Patents for CC-92480
Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
---|---|---|---|---|
CC-92480 | ⤷ Try a Trial | Antiproliferative compounds and methods of use thereof | Celgene Corporation (Summit, NJ) | ⤷ Try a Trial |
CC-92480 | ⤷ Try a Trial | Antiproliferative compounds and methods of use thereof | Celgene Corporation (Summit, NJ) | ⤷ Try a Trial |
>Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for CC-92480
Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
---|---|---|---|---|
CC-92480 | Argentina | AR112268 | 2037-07-10 | ⤷ Try a Trial |
CC-92480 | Australia | AU2018301335 | 2037-07-10 | ⤷ Try a Trial |
CC-92480 | Australia | AU2022287569 | 2037-07-10 | ⤷ Try a Trial |
CC-92480 | Brazil | BR112020000442 | 2037-07-10 | ⤷ Try a Trial |
CC-92480 | Canada | CA3069138 | 2037-07-10 | ⤷ Try a Trial |
>Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |